Evidence map›Paper›PMID 29167001›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2017

[Association between the ALK Gene Status and the Efficacy of First-line 
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].

Mengge Chen, Hui Cao, Yingying Ji, Yuhuan Mao, Shujing Shen, Xingya Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mengge ChenDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
Hui CaoDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
Yingying JiDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
Yuhuan MaoDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
Shujing ShenDepartment of Tumor Radiotherapy, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
Xingya LiDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, 
Zhengzhou 450052, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnaplastic lymphoma kinase (ALK) is one of the major driver genes of non-small cell lung cancer (NSCLC). Several studies have shown that the efficacy of pemetrexed in ALK-positive lung cancer is controversial. The aim of this study is to explore the efficacy of pemetrexed-based chemotherapy in patients with ALK-positive and negative lung adenocarcinoma.

methodsThe clinical data of 98 cases of epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral oncogene (KRAS), V-rafmurine sarcoma viral oncogene homolog B1 (BRAF)-negative patients with advanced lung adenocarcinoma patients who diagnosed by histopathology from January 2015 to April 2016 in the First Affiliated Hospital of Zhengzhou University were collected. The relationships between ALK gene status, clinical characteristics and response and progression-free survival (PFS) were analyzed.

resultsAll of the 98 patients' ALK status were determined. ALK gene fracture fusion occured in 34 cases (34.7%), no fracture fusion in 64 cases (65.3%). All patients underwent first-line pemetrexed and platinum-based chemotherapy, the objective response rate (ORR) was 21.4% and the disease control rate (DCR) was 84.7%. The ORR and DCR of patients with ALK fracture fusion were higher than those without fracture fusion (41.2% vs 10.9%, χ2=23.389, P<0.001; 91.2% vs 81.3%, χ2=4.153, P=0.042), the difference was statistically significant. ALK gene status was not related to age, gender, smoking history and clinical stage. The median PFS of ALK-positive lung adenocarcinoma was 7.1 months (95%CI: 6.1-8.1) and negative was 4.7 months (95%CI: 3.818-5.582), and the difference was statistically significant (χ2=13.269, P<0.001). Cox multivariate analysis indicates that PFS of pemetrexed combined with platinum chemotherapy was independent of gender, age, smoking, staging and platinum. ALK gene fracture fusion is an independent factor affecting PFS (HR=0.392, 95%CI: 0.243-0.634, P<0.001).

conclusionsALK-positive lung adenocarcinoma patients with first-line pemetrexed-based chemotherapy have greater clinical benefit than ALK-negative patients.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedAnaplastic Lymphoma KinaseErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedPemetrexedProto-Oncogene Proteins B-rafReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionALK protein, humanAlk protein, ratAnaplastic Lymphoma KinaseBRAF protein, humanEGFR protein, humanErbB ReceptorsPemetrexedProto-Oncogene Proteins B-rafReceptor Protein-Tyrosine KinasesALKFirst-line chemotherapyFracture fusion geneLung neoplasmsPemetrexed

Identifiers

PMID29167001
PMCPMC5973278
OpenAlexW3025108658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.